Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investment Analysts’ new coverage for Monday, March 25th: Northland Securities initiated coverage on shares of Astera Labs (NASDAQ:ALAB). The firm issued an outperform rating and a $85.00 price target on the stock. Maxim Group began coverage on shares of Alimera Sciences (NASDAQ:ALIM). Maxim Group issued a buy rating and a $10.00 target price on the […]
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
As the proliferative diabetic retinopathy market grows, personalized medicine and research and development will be at the forefront of driving demand....
While it may not be enough for some shareholders, we think it is good to see the Alimera Sciences, Inc. ( NASDAQ:ALIM...